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Introduction
Vertebrates have developed two parallel, but structurally and functionally distinct, vascular systems: the blood and lymphatic vascular systems (1, 7) . The lymphatic vascular system controls tissue fluid homeostasis, absorbs lipids and fat-soluble vitamins from the intestine, and mediates afferent immune responses by transporting lymphocytes and antigenpresenting cells to regional lymph nodes (1, 7) . In addition, malignant cancers can induce lymphatic vessel activation and growth (lymphangiogenesis) within primary tumors and draining lymph nodes, which enhances cancer metastasis to draining lymph nodes and beyond (1, 22) . These findings have fueled a surge of studies aimed at defining the molecular characteristics and functional activities of lymphatic vessels, and identifying molecules that regulate lymphangiogenesis.
Genomic and proteomic studies have identified novel molecular markers and growth factors for lymphatic vessels (2, 23, 48, 52) . Genetic mouse models have characterized the transcription factors PROX1 and SOX18 as master regulators of lymphatic vascular development and differentiation in vivo (12, 56, 65) . These studies indicate that SOX18 expression in a subset of cardinal vein endothelial cells initiates lymphatic vascular development by inducing PROX1 expression (12) . The resulting lymphatic vascular progenitor cells bud off and migrate away from the cardinal vein and form primitive lymph sacs, which subsequently develop into functional lymphatics (12, 56) . PROX1 and SOX18 expression in cultured BVECs triggers these cells to adopt lymphatic-specific molecular and phenotypic characteristics (12, 26, 48) . Conversely, PROX1 knockdown in LECs inhibits the expression of LEC-signature genes and triggers BVEC-signature gene expression(44 and Shin et al., manuscript in preparation). Despite these advances, a detailed understanding of the mechanisms controlling lymphatic vascular development and cell type-specific differentiation remains elusive.
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limiting protein synthesis (10) . This regulation is brought about when mature miRNAs, loaded in the RNA-induced silencing complex (RISC), base-pair with semi-complementary sites within the 3' untranslated region (3'UTR) of target mRNAs. Once base-paired with its target, the miRNA represses translation and/or induces mRNA degradation (10) . Consequently, miRNAs act as novel and potent regulators of the genome. This notion is underscored by recent studies defining critical roles for miRNAs in embryonic development, cell proliferation, cell cycle progression, differentiation, and apoptosis, as well as their contribution to the etiology of several diseases (10, 46, 68) .
Interestingly, functional roles for miRNAs in blood vascular development have recently been defined. Down-regulation of the miRNA processing enzymes Dicer and Drosha have been reported to impair angiogenesis (11, 59) . Moreover, a few miRNAs have been shown to affect human umbilical vein endothelial cell (HUVEC) migration and proliferation in vitro, regulate nitric oxide synthase expression, promote tumor angiogenesis, control vascular inflammation, and directly contribute to numerous vascular phenotypes (11, 59 ).
In the study presented here, we identified and addressed the functional relevance of vascular lineage-specific miRNAs. We first defined the miRNA expression profiles of 
Materials and Methods

Cell Culture
Primary human dermal microvascular LECs and BVECs were isolated from neonatal human foreskins and cultured as previously described (23) . cLECs and HUVECs were purchased from Cambrex (Verviers, Belgium). Human IMR91 dermal fibroblasts (hdFBs)
were obtained from the National Institute on Aging, Bethesda, MD, USA. The immortalized human epidermal keratinocyte line HaCaT was provided by Dr. Norbert Fusenig, German
Cancer Research Center, Heidelberg, Germany(4). Cells, except hdFBs, were propagated in supplemented endothelial cell basal medium (EBM; Cambrex) as described (23) . hdFBs were propagated in D-MEM (Dulbecco's modified eagle medium) supplemented as described above and transferred 12 hrs prior to total RNA isolation to EBM supplemented as described above. Primary cells were used at passage 6.
In vitro miRNA expression profiling
The TaqMan microRNA Assays Human Panel Early Access Kit (Applied Biosystems, Foster City, CA), containing 157 individual human TaqMan microRNA assays, was used for qRT-PCR miRNA expression profiling(5). Total RNA was isolated from biological replicates of 80-90% confluent 10-cm tissue culture dishes using the mirVana miRNA isolation kit (Ambion, Austin, TX). Reverse transcription reactions were performed using 2 ng of total RNA and the microRNA Reverse Transcription kit (Applied Biosystems).
miRNA expression levels of technical duplicates were determined using a 7900HT Fast RealTime PCR System (Applied Biosystems) and comparative threshold cycle (Ct) values acquired after 40 cycles using SDS 2.2 software (Applied Biosystems). TaqMan microRNA assays (Applied Biosystems) for hsa-miR-31, hsa-miR-137, hsa-miR-99a, hsa-miR-125b, hsamiR-95, hsa-miR-326 and human RNU48 were used to confirm lineage-specific expression.
For analysis, detection thresholds were set to 0.04 units of fluorescent intensity and when a miRNA Ct value was undetermined in both technical replicates, Ct values of 41 were assigned. Datasets were normalized relative to let-7a and miR-16 using the formula: 
FACS isolation of endothelial cells from mouse colons
Animal experiments in mice were approved by the Kantonales Veterinäramt Zürich.
Colons were excised from sacrificed female FVB mice (Charles River, Sulzbach, Germany;
12-16 weeks old; n=8), opened longitudinally, washed in cold PBS and placed in 1 mM DTT.
Mucus was gently removed by scraping. Small tissue pieces were digested with 8 mg/ml collagenase IV (Invitrogen, Carlsbad, CA), 0.5 mg/ml DNaseI (Roche, Rotkreuz, Switzerland) and 5 mM CaCl 2 in PBS at 37 0 C for 15 min. After passing through a 70 µm cell strainer (BD Biosciences, Franklin Lakes, NJ), the resulting cell suspensions were centrifuged at 500 g for 10 min and resuspended in 2% FBS-supplemented PBS, containing 1 mM EDTA.
Antibodies used for FACS sorting were: allophycocyanin (APC)-conjugated rat anti- Immunofluorescence stains were performed as described (25, 35) 
Microarray analyses
All transfections were carried out using the Basic Nucleofector Kit for primary mammalian endothelial cells (Amaxa AG, Cologne, Germany). 500,000 LECs were transfected with 2 µM Pre-miR-31 or Pre-miR-Neg molecules (30) in biological duplicate and total RNA isolated using the mirVana isolation kit 48 hours post-transfection. The transcriptome profiles of these cells were defined using the Applied Biosystems Human
Genome Survey Microarray v2.0 as described (54) . Briefly, dioxigenin-UTP-labeled cRNA was generated from 1.5 µg of total RNA using the NanoAmp RT-IVT Labeling Kit (Applied Biosystems). 20 µg cRNA were fragmented and hybridized to the microarrays using the Raw data were normalized using Quantile normalization available from R/Bioconductor (14) . Present calls were defined based on average signal-to-noise ratios (S/N ratio) >3 and quality (error) values <5,000 (54) . Feature signal intensities were converted to log 2 values. miR-31-repressed genes were identified based on present calls in both Pre-miRNeg arrays, log 2 (Pre31/PreNeg) ≤-0.59 and p-values <0.05, while miR-31-induced genes were present in both Pre-miR-31 arrays, had log 2 (Pre31/PreNeg) ≥0.59 and p-values <0.05. Pvalues were calculated using empirical Bayes statistics for differential expression (55) .
mRNA quantitative RT-PCR analyses
To confirm the microarray data, the mRNA expression levels of selected candidate miR-31-regulated LEC-and BVEC-signature genes were analyzed in triplicate by (Hs01007340_m1; all from Applied Biosystems). The probe and primers for LYVE-1 were as described (23) . 25 ng of cDNA, generated using the High Capacity cDNA Archive Kit (Applied Biosystems) were used. Each reaction was normalized to β-actin expression (54) .
Detailed analysis of PROX1 mRNA and protein levels
To further characterized miR-31 regulation of PROX1, 500,000 LECs were transfected with 2 µM or 4 µM Pre-miR-31 (n=4) or Pre-miR-Neg (n=4) molecules, or 4 µM Anti-miR-31 (n=2) or Anti-miR-Neg (n=2) molecules (6) . Total RNA and whole cell protein lysates were isolated using the mirVana PARIS kit 48 hours post-transfection. qRT-PCR analysis of PROX1 mRNA was preformed as described in the main text.
Northern blot analyses were performed on 1 µg total RNA. PROX1 mRNA was detected using purified PROX1 3'UTR γ
32
ATP end-labeled probes generated from a NotIlinearized human PROX1 3'UTR plasmid (YH1551; provided by Dr. Young Kwon Hong, University of Southern California, Los Angeles, CA). The membrane was then stripped and β-actin detected using γ 32 ATP end-labeled human β-actin oligonucleotides (5'-GTGAGGATCTTCATGAGGTAGTCAGTCAGGT-3').
For western blotting, 25 µg of the protein lysates were resolved by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were probed with rabbit polyclonal antihuman PROX1 (RELIATech, Braunschweig, Germany) and mouse monoclonal anti-human β-actin antibodies (Sigma-Aldrich), detected using horseradish peroxidase (HRP)-conjugated secondary antibodies and standard chemiluminescence (54 
Luciferase Reporter Assays
For miR-31 overexpression optimization, 500,000 LECs were co-transfected with 0.7 µg pMIR-Luci/miR31BS, 0.7 µg pMIR-REPORT β-Galactosidase Table 1 ). Firefly and Renilla luciferase activities were monitored 48 hours after transfection using the Dual-Luciferase Reporter Assay System (Promega). PROX1 3'UTR/CDS-Renilla luciferase RLUs were normalized to firefly luciferase RLUs. Both the Dual-light and Dualluciferase assays were performed in triplicate with 20 µL of cell lysate.
Xenopus microinjection and whole-mount in situ hybridization
Xenopus studies were conducted under protocols approved by the Veterinary Office of the Canton of Zürich, Switzerland. Xenopus laevis eggs were obtained by hormoneinduced laying, fertilized in vitro and prepared for microinjection as previously described (21). 
Zebrafish microinjection
Transgenic TG(fli1a:gfp) y1 (37) and plcg1 t26480 zebrafish lines were maintained in the Venous sprouts were quantified at 48 hpf and statistical significance analyzed using the Student's t-test. For imaging, embryos were mounted in 0.8% low melting point agarose in a dish with a cover slip replacing the bottom. Imaging was performed with a Leica SP2 confocal microscope (Leica Microsystems) using a 20x objective.
Results
BVEC versus LEC lineage-specific miRNA expression
Using a TaqMan-based qRT-PCR profiling platform (5) we defined the in vitro expression profiles of 157 human miRNAs in primary LECs and BVECs, as well as two nonendothelial cell types (HaCaT keratinocytes and dermal fibroblasts (hdFBs)) (Supplementary Table 2 ). Following data normalization, expression profiles for each cell-type were defined by setting the Ct value present call cut-off at 34 (Supplementary Table 2 ). Most of the miRNAs analyzed were expressed at comparable levels in both LECs and BVECs (Supplementary Figure 1) . Nevertheless, based on a two-fold or greater differential expression, 16 candidate LEC-and 30 candidate BVEC-signature miRNAs were identified (Table 1) . Using a p-value cut-off of ≤0.05, 2 LEC-signature miRNAs (miR-95 and miR-326) and 4 BVEC-signature miRNAs (miR-137, miR-31, miR-125b and miR-99a) were identified (Table 1) . Individual
TaqMan miRNA assays confirmed the vascular lineage specificity of these miRNAs. miR-95
and miR-326 were, on average, 46-fold and 7-fold higher in LECs than in BVECs, respectively ( Figure 1A ). Conversely, miR-137 expression was 124-fold higher in BVECs than in LECs, miR-31 was 48-fold higher in BVECs, and miR-125b and miR99a were 3-fold more abundant in BVECs ( Figure 1B ).
LEC-and BVEC-signature miRNA expression patterns are maintained in vivo
We next isolated BVECs and LECs from the colons of 8 adult mice by FACS sorting, using the leukocyte marker CD45, the pan-endothelial marker CD31 and the LEC marker (18) . We obtained 1500 to 25000 LECs and 2500 to 55000 BVECs, from which total RNA was extracted and used for ex vivo qRT-PCR miRNA profiling. Based on a 1.5-fold or greater differential expression, miR-31 was indeed more strongly expressed by
BVECs than LECs in 6 of 8 mice analyzed (Figure 2A ). The degrees of miR-31 differential expression between mouse BVECs and LECs in vivo were less pronounced than those observed between in vitro cultured human endothelial cells. Nevertheless, statistical analysis of these in vivo data confirmed that the differences in miR-31 expression between mouse BVECs and LECs were statistically significant in 6 out of the 8 mice studied (Figure 2A ).
The LEC-signature expression pattern of miR-326 and the BVEC-signature classifications of miR-125b and miR-99a were also confirmed, while no major changes were found for miR- Figure 2) . miR-95 is not present in mice. submitted for review). Interestingly, twice as many transcripts encoding LEC-signature molecules (9.6%) than BVEC-signature molecules (4.8%) were reduced following miR-31 overexpression ( Figure 3A and B, and Supplementary Table 3) . Also, approximately 4 times more BVEC-signature genes (4.6%) were induced/stabilized following miR-31 overexpression compared to LEC-signature genes (1.1%) ( Figure 3A and B, and
(Supplementary
Supplementary Table 4 ). Corroborating the microarray data, qRT-PCR experiments confirmed that four LEC-signature genes (EDNRB, PROX1, PPP1R9A, HOXD10) and two BVEC-signature genes (ICAM1, SELE) tested were significantly less abundant in the PremiR-31 samples compared to Pre-miR-Neg control ( Figure 3C and D) . Furthermore, we also validated the up-regulation of the miR-31-induced BVEC-signature genes MMP1 and RGS4
( Figure 3E ).
miR-31 inhibits PROX1 protein translation
Amongst the miR-31-repressed target genes was PROX1, an essential lymphaticspecific transcription factor (1, 7) . qRT-PCR analysis confirmed that transfection of LECs with 4 µM Pre-miR-31 resulted in a ≥60% reduction in PROX1 transcripts ( Figure 4A ), which was further verified by Northern blotting (Supplementary Figure 5) . Importantly, immunoblotting revealed a consistent decrease in PROX1 protein levels by <40% following miR-31 overexpression ( Figure 4B and C) . Similar, but less consistent, results were observed after transfection with 2 µM Pre-miR-31 (Supplementary Figure 6) . Conversely, loss-of miR-31 function in BVECs, via transfection of HUVECs with miR-31 inhibitor molecules (AntimiR-31), resulted in a 1.7−3.1-fold increase in PROX1 mRNA levels ( Figure 4D ). PROX1
protein remained undetectable in these samples (data not shown).
PROX1 is a direct target of miR-31 post-transcriptional regulation
PROX1 was not predicted to be a target of miR-31 by TargetScan(17, 39 Table 6 ).
To test the functional relevance of these candidate miR-31 binding sites luciferase reporter genes containing a full-length PROX1 3'UTR (PROX1 FL), 6 PROX1 3'UTR fragment (PROX1 F1-6) ( Figure 5A ), or a PROX1 coding sequence (CDS) were constructed.
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The activities of these chimeras were monitored following miR-31 gain-of-function in LECs (
Figure 5B Table 3 ) and 36% of the miR-31-induced BVEC-signature genes (Supplementary Table 4 ) were similarly differentially expressed following PROX1 depletion from LECs.
miR-31 regulates vascular development in vivo
During embryogenesis PROX1 is expressed in a subpopulation of cardinal vein endothelial cells that give rise to the mammalian lymphatic vascular system(1, 7). The BVEC-specific expression of miR-31, together with its ability post-transcriptionally repress numerous BVEC-and LEC-signature genes (Supplementary Tables 3 and 4) , including Prox1, suggested that this miRNA might play a role in vascular development. As many of the BVEC-and LEC-signature genes targeted by miR-31 also play a major roles in Xenopus vascular development (9, 20, 45) , we reasoned that ectopic expression of miR-31 in early
Xenopus embryos might interfere with lymphatic vascular development. To investigate this, 2-cell stage Xenopus embryos were unilaterally microinjected with human Pre-miR-31 or PremiR-Neg molecules. Lymphatic and blood vascular system development were then monitored in stage 39 embryos using whole-mount in situ hybridization (ISH) for specific lymphatic and blood vascular marker genes (28, 29, 45) .
No gross developmental defects or externally visible phenotypes were observed following Pre-miR-Neg or Pre-miR-31 microinjection into Xenopus embryos ( Figure 6 ).
Moreover, prox1 and vegfr3 marker gene analysis demonstrated that lymphatic vascular 21 development progressed normally in 95% and 79% of the Pre-miR-Neg control embryos, respectively ( Table 2 ). The embryos had well-defined and clearly visible lymph hearts, lymph vessels, and punctate patches of LECs in their tails ( Figure 6A and B) . In contrast, a dosedependent increase in lymphatic vascular defects was observed in Pre-miR-31 injected embryos. Specifically, vefgr3 ISH demonstrated that the percentage of embryos with lymphatic vascular defects as monitored by the loss of vegfr3-positive lymphatics sprouting from the lymph hearts progressively increased from 6.1 to 76.2% as the amounts of Pre-miR-31 molecules increased from 1 ng to 50 ng (Table 2) . Generally, lymph hearts were present in these embryos but appeared smaller and less well-defined compared to control embryos ( Figure 6A and B) or the uninjected side of the Pre-miR-31 embryos (data not shown).
Moreover, lymphangiogenesis, scored by the presence of vegfr3-expressing lymphatic vessels sprouting from the lymph heart, was either strongly reduced or absent in the presence of excess miR-31 ( Figure 6A and B). These phenotypes were similar to those observed following morpholino inhibition of vegfc, where lymphangiogenesis was disrupted in the lymph heart region of 67-100% (N=3, total embryos analyzed: 71) of the injected Xenopus embryos (Supplementary Figure 7) .
Pecam1 expression was used to monitor blood vascular system development in PremiR-Neg and Pre-miR-31 microinjected Xenopus embryos. In control embryos, all of the major blood vascular structures such as the posterior cardinal veins and the dorsal aorta were clearly visible, and angiogenic sprouting of intersomitic veins occurred normally in 73% of the Pre-miR-Neg injected embryos ( Figure 6C and Table 2 ). By comparison, the percentage of embryos displaying unilateral intersomitic vein growth and/or guidance defects progressively increased from 0% to 76% with increasing amounts of Pre-miR-31 injected ( Figure 6C and Table II) .
Gain-of-function phenotypes can occasionally be attributed to the off-target effects associated with non-physiological expression levels of an siRNA or miRNA (41, 51 (Table 3 and Figure 7A ). In agreement with our Xenopus studies, a significant dose-dependent reduction in venous sprouting was observed in Pre-miR-31 injected embryos compared to embryos injected with 340 pg PremiR-Neg molecules or to uninjected controls (Table 3 and Figure 7 ). The increase in venous sprouting observed in Pre-miR-Neg injected embryos ( Figure 7B and C) appears to be a stress response, which we have also observed in a number of unrelated control injections (data not shown). Conversely and importantly, miR-31 overexpression led to a highly significant reduction in venous sprouting and no other developmental defects were observed in these embryos (Table 3 and Figure 7A and D).
Venous sprouting and lymphangiogenesis were also monitored in zebrafish embryos following injection of increasing concentrations of morpholino oligonucleotides (MO)
targeting both mature and precursor dre-miR-31. Significant vascular phenotypes could not be specifically attributed to loss-of miR-31 activity in these embryos (data not shown). Taken together, our miR-31 gain-of-function studies in Xenopus and zebrafish embryos indicate that appropriate expression levels of miR-31 during vertebrate embryogenesis are required for normal lymphatic and blood vascular development.
Discussion
In the study presented here we first defined the in vitro expression profiles of 157 human miRNAs in primary human LECs and BVECs using a TaqMan-based qRT-PCR profiling platform, whose increased sensitivity facilitated the detection of at least twice as many miRNAs in HUVECs as previously reported (19, 34, 50, 58, 66) . We also found that one of the most highly expressed HUVEC miRNAs, miR-126 (19, 34, 50, 58, 66) , was >600 times more abundant in both endothelial cell types than in either keratinocytes or fibroblasts. Moreover, their relative contributions to the isolated total RNA might vary, thus contributing to larger variability in miRNA expression patterns. In addition, the ex vivo miRNA expression profiling studies were technically challenging as the whole process took more than 2 hours and only a few thousand endothelial cells could be isolated by high-speed cell sorting.
Consequently, the smaller amounts of isolated total RNA, reduced RNA quality and possible gene expression changes incurred during the 2-hour isolation procedures likely contributed to Table 6 ). Taken together, our transcriptome profiling and biochemical studies have revealed a novel, highly conserved BVEC-specific post-transcriptional regulatory mechanism that suppresses PROX1 expression in the blood vasculature.
Our findings also suggested that miR-31 expression in the developing blood vascular endothelium could regulate the acquisition of lymphatic-specific characteristics and, thus, vascular development in vivo. Multiple miR-31 loss-of-function studies using morpholino oligonucleotides were performed in both wild-type and plcg1 mutant zebrafish embryos.
Statistically significant vascular phenotypes were not observed in zebrafish embryos injected with low to moderate (≤10 ng) amounts of MOs (data not shown). This suggests that the miR31-mediated regulation of vascular development identified here is redundant. This is not surprising, since miRNAs frequently function cooperatively (3, 15, 17) , which in turn complicates the attribution of specific functions to individual miRNAs (53) . In contrast, Lymphatic and blood vascular development was monitored by whole mount in situ hybridization of embryos microinjected with Pre-miR-31 and Pre-miR-Neg. The number and frequency of lymphatic and blood vascular developmental defects, as scored based on the presence of several lymphatic and blood vascular structures, are presented. The activities of luciferase constructs containing miR-31BS, PROX1 FL and PROX1 F2 decreased significantly following miR-31 overexpression (Pre-miR-31; n=3) in LECs compared to negative controls (Pre-miR-Neg; n=3). (C) miR-31BS and PROX1 FL reporter gene activities increased significantly following miR-31 inhibition (Anti-miR-31; n=3) in HUVECs compared to negative controls (Anti-miR-Neg; n=3). miR-31 loss-of-function also enhanced the activities of PROX1 F1 and PROX1 F2 constructs, but these differences were not statistically significant. (D) miR-31 mutant binding site full-length and F2 PROX1 3'UTR (PROX1 FLmut and PROX1 F2mut) luciferase activities showed no major change following miR-31 overexpression (Pre-miR-31, n=3) or knockdown (Anti-miR-31, n=3). Data were normalized to firefly luciferase activities and are shown as mean relative abundances +/-SE. ns, not significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). . Pre-miR-31 injected embryos exhibited marked defects in lymphatic vascular development, the most striking of which was impaired lymphatic vessel sprouting (arrowheads) from the lymph heart (arrow). (C) Pecam1 ISH showed that intersomitic vein growth (arrowheads) was unilaterally misguided or delayed in embryos with elevated levels of miR-31. 
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